$DECN triple corrected.
recovery. OTC $0.43
Called
$DECN triple corrected.
recovery. OTC $0.43
Called 9/9/13 $0.30
Website
David-Goliath Fight
Over Glucose Tests For Diabetics
Hits Boiling Point Forbes
Wed, Apr 20)
Shares Outstanding: 25.16M
Float: 16.61M
% Held by Insiders: 15.45%
% Held by Institutions: N/A
Headlines
Decision Diagnostics Corp. develops smart phone based remote electronic medical record technologies. The company offers prescription drugs; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It distributes brand name rx and non-rx diagnostics products, as well as various lines of ostomy, wound care, and post-surgery medical products. The companys line of devices for blood glucose home testing includes Genstrip50 test strips, as well as concepts for blood testing monitors. Decision Diagnostics Corp. also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physicians practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. In addition, it offers IT services in various medical care markets by developing smart phone applications to be used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp was founded in 2000 and is based in Westlake Village, California .
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
Top 5 Most Recently Viewed Articles
Aurelia Cellular Vitality just hit the U. S. market on February 17, 2026, and this ain't just another beauty brand strutting in with flashy ads and pretty bottles. They’re packing some serious science behind their hair, skin, and nail supplements formulated with their proprietary Eternacell™ complex designed to hit cellular-level vitality hard—think anti-aging but...
Continue Reading
Exciting Developments Ahead for European Wax Center, Inc. European Wax Center, Inc. (NASDAQ: EWCZ), recognized as a prominent franchisor specializing in out-of-home waxing services across the United States, is gearing up to unveil significant financial reports. Anticipation builds as the company prepares to disclose its fourth-quarter and fiscal year 2024 financial...
Continue Reading
A Comprehensive Look at Nutrient Intake Measurement A recent innovative framework designed to measure nutrient absorption offers a new perspective on how we understand the nutrients our bodies utilize. Traditional methods often focus solely on the total nutrient content, neglecting a crucial factor in nutrient intake: how much of those nutrients are actually absorbed by...
Continue Reading
Back in the day, Jennifer Cable took the reins as President of Thorlabs, positioning herself at the forefront of optical technology. Fast forward to her latest move—she joined J2 Ventures' advisory board, which sent ripples through the deep tech landscape. Traders were buzzing; they knew this wasn’t just another face in the crowd. With over $250 million under...
Continue Reading
Understanding Bank of America Stock Dividends Bank of America Corporation (NASDAQ: BAC) is set to announce its earnings for the second quarter soon, generating buzz among investors regarding its dividend potential. Its current annual dividend yield stands at 2.20%, which translates to a quarterly dividend of 26 cents per share or $1.04 annually. Calculating Monthly Income...
Continue Reading